Therapeutics for Macular Degeneration and Other Age-Related Disorders
Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues
THERAPEUTIC STRATEGY
Increase expression of ELOVL2 by: 1) Epigenetic rescue and 2) ELOVL2 gene therapy
LEAD INDICATION
Age-related Macular Degeneration / Geographic Atrophy
Copyright © 2020 Visgenx, Inc. - All Rights Reserved.
Powered by GoDaddy